ABSTRACr Nedocromil sodium (FPL 59002) is a pyranoquinoline dicarboxylic acid that has been developed for the management of bronchial asthma. We report the results of a double blind group comparative trial in which the disodium salt of nedocromil delivered by pressurised aerosol and a placebo were compared in the management of patients with a diagnosis of bronchial asthma who entered the double blind period on a minimum dose of beclomethasone dipropionate. In almost all the assessments of clinical activity nedocromil sodium was shown to be more effective than placebo. These include improvements in diary card symptom scores, reduction in concomitant use of a bronchodilator aerosol, and patients' and investigators' assessments of efficacy. Unwanted effects were few and mild. No patients were withdrawn from the trial.
Nedocromil (FPL 59002) is a pyranoquinoline dicarboxylic acid (chemical name 9-ethyl-6, 9-dihydro-4,6-dioxo-10-propyl-4H-pyrano (3,2-g) quinoline-2,8-dicarboxylic acid) and its disodium salt (FPL 59002KP) was identified from a range of pharmacological and immunological tests as a compound worthy of clinical evaluation in asthmatic patients. In antigen challenge studies nedocromil sodium was shown to protect against the immediate reaction, and the results suggested that the compound may be useful in the treatment of bronchial asthma.
We report here the results of a double blind group comparative trial of nedocromil sodium and placebo in the management of patients with bronchial asthma who were currently being treated with beclomethasone dipropionate and a 12 adrenergic agonist bronchodilator aerosol to control their symptoms.
Patients and methods The other group received two inhalations four times daily from an identical placebo pressurised aerosol containing the same propellants and surfactant but without the active drug. Both treatments were continued for 28 days. Before starting on the trial aerosols each patient completed a diary card for two weeks to establish baseline values. They rated symptoms of night time and daytime asthma, morning chest tightness, and cough on a 0-4 scale related to each symptom-for example, night asthma would be rated from 0 (undisturbed sleep) to 4 (being awake all night). Patients were supplied with a mini Wright peak flow meter and they recorded the best of three readings morning and evening on the diary card. They also recorded all medication taken, including the test medication.
At each clinic visit the severity of the patient's asthma was assessed on a 0-4 scale (0-no symptoms, 1-mild, 2-moderate, 3-severe, 4-very severe). FEV1 and FVC were measured with a Vitalograph and peak expiratory flow rate (PEFR) was checked using the patient's own peak flow meter. Patients were asked about complaints which might be considered adverse reactions to the trial treatment and these were rated on the assessment forms as possibly, probably, or unlikely to be due to treatment or "don't know." Before and after the trial treatment blood and urine samples were taken for routine analysis.
Only patients with a score of 2 or more for at least one asthma symptom for seven days or a PEFR variability of 20% were included in the double blind period of the trial. They were also required to show that they were able to use a pressurised aerosol and peak flow meter correctly and that they understood how to complete the diary card. Mean symptom severity scores of daytime and night time asthma, morning tightness and cough, and use of a bronchodilator aerosol were calculated from the diary cards for each week of the double blind period and were compared with means in the baseline period. Results are shown in tables 1 and 2.
Mean decreases in severity scores were greater in the nedocromil group than in the placebo group for all symptoms and differences between the groups were significant for daytime asthma for all treatment weeks. Differences in morning tightness were significant for the first and second weeks and for cough in weeks 1 and 4. Mean PEFR values for the treatment period were slightly effective, and one not effective at all. No compared with mean values for the baseline. Read-patient thought his or her condition had been made ings taken within four hours of an inhalation of a worse. On the other hand, of the 17 patients taking bronchodilator were excluded. Only those patients placebo, eight thought that the treatment was very for whom complete data were available (12 having effective or moderately effective and one patient active and 15 placebo preparations for the morning thought that it was slightly effective, but another peak flow rate, 10 having active and 15 placebo seven found no effect and one felt that his condition preparations for the evening) were included in the was made worse. Differences between groups were analysis.
significant at the 5% level with the Mann-Whitney Mean PEFR increased in both groups and no test. The investigator also rated nedocromil as more significant differences were noted between groups effective than placebo (p < 0-01). (table 2) . Use of inhaled bronchodilators fell in both Complaints that might have been adverse reacgroups during the study and this fall was significantly tions to treatment were few and relatively mild in greater in the nedocromil treated group during three both groups. Four patients taking nedocromil weeks of the treatment period (table 3) . sodium had complaints. One patient complained of Patients' as well as the investigator's ratings of the cough and loss of voice and one of headache and a effectiveness of treatment were significantly in sore throat; one said that the aerosol had a bitter favour of nedocromil. Of the 13 patients taking taste. One patient complained of dizziness but this nedocromil, 11 thought the treatment was very was not thought by the investigator to be drug effective or moderately effective, one considered it related. Three patients having placebo had com- 
